Because atopic dermatitis (AD) is a chronic, relapsing disease, treatment requires the use of both active therapy to control flares and preventative maintenance therapy to promote integrity of the skin barrier. In this third of four sections, important clinical considerations for the treatment of pediatric AD are reviewed. Emerging therapies in development for pediatric AD are introduced. of FUSE Health (Toronto, ON) provided professional medical writing services and organizational support for this manuscript.
The chronic and recurrent nature of pediatric atopic dermatitis (AD) requires the use of both active therapy for flares and maintenance therapy to promote integrity of the skin barrier and prevent future flares. The treatment of pediatric AD has historically been limited to topical therapies, including both non-pharmacologic and pharmacologic agents, as well as off-label systemic therapies. Systemic therapy is warranted for patients who have inadequate disease control (persistent severity and extent or significant impact on quality of life) despite appropriate treatment with topical therapy and/or phototherapy. 1 Choice of therapeutic agent takes into consideration whether the topical or systemic therapy is being used as a short-term strategy to control a flare or as a longer term maintenance regimen. Patient-, disease-, and treatmentrelated factors must be considered ( Table 1 ). The therapeutic landscape of pediatric AD is changing rapidly as novel small molecule and biologic therapies are being developed to specifically target disease pathways. Here we review the different classes of therapy available for pediatric AD and provide practical guidance for their use.
Skin barrier dysfunction is crucial to disease pathogenesis, 2 and emollients play a key role in the prevention, treatment, and maintenance of pediatric AD. 3 Early use of daily emollients can prevent or delay disease onset in neonates at high risk for AD. 4, 5 Emollient use in AD has been shown to lower investigator-assessed disease severity scores and the use of topical corticosteroids (TCS) and to prolong time to flare. 6 In cases of severe AD, emollients should be used as a supplement to therapeutic treatment and may help to reduce signs of inflammation, including pruritus, erythema, fissuring, and lichenification. 7 There is no convincing evidence to support the use of one type of moisturizer over another, and no studies define an optimal amount or frequency of application. 6, 8 The choice of emollient should be made based on patient preference and health-care provider (HCP) guidance.
There is no current evidence-based standard for frequency or duration of bathing and most recommendations on bathing and bath additives are based on low-level evidence and expert consensus. 7, 9 Our group defines regular bathing as once daily, when tolerated. Expert consensus recommends bathing with lukewarm water, followed by immediate application of moisturizer. 8 When indicated, prescribed topical therapy should precede the application of moisturizer. In moderate-to-severe AD, regular bathing with warm water helps to hydrate the skin and remove potential skinexacerbating agents such as serous crusts, allergens, and irritants. 7 The use of neutral pH, fragrance-free, hypoallergenic soaps or non-soap cleaners are recommended and should be used as required. 8 In addition, common allergic triggers should be identified and avoided, as appropriate. 8 There is limited evidence to support the routine use of bleach baths, soak and smear techniques, and wet wrap therapy (WWT); larger scale randomized controlled trials (RCTs) are needed to better understand their value in disease management. 7, 10, 11 Bleach baths, consisting of soaking for 5-10 minutes, twice weekly in a diluted bath of sodium hypochlorite, do not appear to be more effective in decreasing AD severity compared to water baths alone 12 ; however, these findings are limited by single-centre trial designs with small study populations and relatively short follow-up assessments of 2-12 weeks. WWT, consisting of TCS administered under a layer of wet cotton bandages or garments, may be more effective than conventional treatment with TCS; however, the quality of evidence is low and results to support this modality are inconsistent across studies. 13 WWT is used as short-term rescue therapy for severe AD flares and there is no standard protocol in terms of duration of treatment, frequency of application, and steroid potency used.
Diet and Oral Supplements
There is no consistent evidence to recommend food avoidance or dietary supplements to reduce or prevent AD symptoms. While there is low-level evidence for specific food avoidance leading to AD improvement in patients with identified food allergies, 14, 15 there is no evidence to support empiric food avoidance in all pediatric AD patients. 14, 15 There is limited evidence to support vitamin D or symbiotic supplementation. 16, 17 Currently available probiotic strains do not result in clinically meaningful differences in investigator-assessed outcomes. 18 Early prebiotic supplementation may be of benefit, but more evidence is needed to support a clinical recommendation. 19 Maternal supplementation does not appear to affect the incidence of childhood allergy. 20
Complementary and Alternative Medicines
There is little evidence to support the use of most complementary and alternative medicines to treat pediatric AD. Although studies are increasing, many have insufficient data to suggest a benefit. Oral unsaturated fatty acids, including evening primrose oil, borage oil, polyunsaturated fatty acids, or animal and fish oil, are not recommended for treatment of AD. 21, 22 The evidence for treatment of AD with topical or oral Chinese herbal medicine is limited and inconclusive. 23 Topical use of crude plant extracts is not recommended for treatment of AD and may even cause contact sensitization and contact dermatitis. 21 Some other alternative treatments have limited evidence to suggest therapeutic benefit. These include acupuncture/acupressure, hypnosis, massage, biofeedback, balneotherapy, sunflower seed oil, coconut oil, pale sulfonated shale oil, vitamin B12, and select herbal preparations. 24 Olive oil should be avoided and may exacerbate xerosis and AD. 25 Treatments such as vitamin E, East Indian Sandalwood Oil, melatonin, L-histidine, and Manuka honey have very limited evidence and are not recommended. 26 
Eczema Action Plan
Eczema action plans (EAPs) are based on a shared decisionmaking process between the HCP and patient or caregiver. 7, 27 Treatment of severe AD should incorporate an individualized written EAP, 27 which has been shown to improve disease understanding, 28 aspects of management, [28] [29] [30] psychological outcomes, 29 and patient/caregiver satisfaction. 31
Pharmacologic Therapies
Antihistamines A recent Cochrane review found no consistent evidence to support H1 antihistamines as "add-on" therapy for AD. 32 Oral non-sedating antihistamines used in the management of pruritus do not have any added benefit in the treatment of AD. 1, 32 Sedating antihistamines should not be used in the routine management of AD as their use in school-age children may negatively affect school performance 1 and has been linked to a prolonged QT interval in some cases. 33 
Topical Therapy
Topical therapy using TCS, topical calcineurin inhibitors (TCI), and/or phosphodiesterase 4 (PDE4) inhibitors is the first-line pharmacologic therapy for pediatric AD. Medication choice should be based on patient-, disease-and treatmentrelated factors. A summary of available topical therapies for pediatric AD appears in Table 2 .
Topical Corticosteroids
Traditionally, TCS have been used as first-line topical therapy, with more than 110 RCTs over a 60-year span. 34 TCS are anti-inflammatory and anti-pruritic agents that act nonspecifically to suppress the release of pro-inflammatory cytokines. [34] [35] [36] They have a fast onset of action 37 and can be used to treat acute flares or as maintenance therapy. 34, 35 Proactive maintenance therapy with intermittent TCS plus emollient can reduce recurrence of flares 38 and may prevent sensitization to aeroallergens in pediatric AD. 39 TCS are classified based on potency. 36 The Eczema Society of Canada provides a concise summary chart of topical therapy formulations for HCPs as well as additional resources for both patients and HCPs (available at www. eczemahelp. ca). There are no guidelines regarding optimal dosing and quantity of TCS application in pediatric AD, 40 although the use of the fingertip unit (FTU) can be suggested as a practical measure, with 1 FTU covering a skin surface area of approximately 2 adult hands' palms or more specifically 312-257 cm 2 in males and females, respectively. 41 Treatment with TCS is tailored based on body area to be treated, severity, and patient preference in terms of vehicle, cost, and availability. Of the various vehicles that exist (creams, ointments, foams, gels, lotions, sprays, and solutions), certain ones may be more suitable based on body area to be treated. 36, 40 Using an appropriate formulation and potency is important for treatment success.
Although adverse effects of TCS are minimal when used appropriately, 42 patient and caregiver fears related to TCS are common. 43 Appropriate counselling and patient education are important to ensure treatment compliance, and ultimately, success. Education of general practitioners and pharmacists may help with adherence. [44] [45] [46] Appropriate use of TCS, even long term, has not been shown to lead to skin atrophy 47 and patients should be counselled accordingly.
Adverse effects increase with higher potency, occlusion, thinner skin areas, younger age, disease severity, and duration of use. 46 Hypothalamic-pituitary-adrenal axis suppression is a rare systemic complication that is increased with high-potency TCS and augmented in children due to greater surface-area-to-volume ratio. 42, 48, 49 Contact allergies to the drug or ingredients of the formulation are an important consideration in patients who worsen with proper TCS application.
Topical Calcineurin Inhibitors
For almost two decades, TCI have been approved by the US Food and Drug Administration (FDA) and by Health Canada for the treatment of non-immunocompromised AD patients unresponsive or unsuitable for conventional therapy. TCI act by inhibiting pro-inflammatory cytokine production. 50 Tacrolimus ointment (0.03%) and pimecrolimus cream (1%) are approved as short-term and non-continuous chronic treatment of AD in Canada and Europe for children ≥2 years of age, with proven efficacy in pediatric AD. In addition, 0.1% tacrolimus is approved for treatment of moderate-severe AD in children 16 years of age and older. A meta-analysis of 19 studies in pediatric AD showed similar efficacy and safety outcomes between tacrolimus and pimecrolimus. 51 A systematic review of topical therapy use in children under 12 years of age showed that data documenting the efficacy and safety of long-term use of TCI are robust in comparison to long-term use of mid-to high-potency TCS. 52 TCI are also safe to use long term on all areas of the body, including sensitive areas such as the face; however, stinging may occur with application on very inflamed skin. 50, 53 Despite the FDA boxed warning regarding malignancy risk with TCI, this is not supported by the current scientific evidence and patients should be counselled appropriately. [54] [55] [56] 
Topical Phosphodiesterase 4 Inhibitors
Crisaborole ointment (2%) is indicated for topical treatment of mild-to-moderate AD in patients ≥2 years of age. It inhibits PDE4, thereby preventing pro-inflammatory cytokine production. 57 Crisaborole was deemed safe in a 48-week open-label safety extension study, with the most common adverse event (AE) being application site pain (4.45% vs 1.20%). 57 Although it is a safe option, trials have shown modest efficacy compared to placebo in the short-term, with no head-to-head trials. [58] [59] [60] [61] Efficacy of maintenance therapy with crisaborole has not been studied-further controlled and long-term studies are needed to confirm its use as maintenance therapy.
Phototherapy
Phototherapy, with concomitant emollients and TCS, may be an appropriate treatment option for moderate-to-severe pediatric AD when available. Narrowband (NB)-UVB is usually the first choice amongst the different phototherapy options in pediatric populations considering its availability, efficacy, and safety. 1 It not only acts to accelerate cell migration, wound healing, and barrier repair, but also promotes antimicrobial peptide production and suppresses pro-inflammatory cytokines. 62 Small, non-randomized prospective studies have demonstrated reduction in both objective severity scores as well as patient-reported outcomes in pediatric AD. 63, 64 The practical aspects of implementing phototherapy in pediatric AD pose a challenge, particularly in younger children who may not be able to sit still and follow instructions in the photobooth. Frequent travel and missed time from school or work may make frequent clinic visits impractical. The short-term adverse effects of UVB phototherapy include erythema, blistering, xerosis, pruritus, sunburn, and recurrence of herpes simplex virus infections. 65 Long-term adverse effects are not known, and the theoretical risk of photocarcinogenesis and photoaging, especially in children, remains unconfirmed. 62, 65 
Systemic Therapies
Several systemic therapies are used both on-and off-label for the treatment of moderate-to-severe pediatric AD refractory to topical therapy and/or phototherapy. These include methotrexate (MTX), cyclosporine A (CsA), azathioprine (AZA), mycophenolate mofetil (MMF), prednisone, and biologics which currently only include dupilumab. Several clinical guidelines have published recommended dosing for the pediatric population. 1, 21, 66 A summary of available systemic therapies for pediatric AD appears in Table 3 .
The use of systemic agents in pediatric AD is typically off-label, with limited supporting evidence. At this time, the only systemic therapies indicated for the treatment of 68 Most systemic agents require baseline and follow-up laboratory monitoring, with the exception of prednisone and dupilumab. Much of the safety data for systemic therapy in pediatric AD are extrapolated from other disease groups and adult studies, and few randomized trials exist in the pediatric population. There is only 1 published RCT investigating systemic therapies for treatment of pediatric AD comparing MTX and CsA in 40 children with severe disease. 68, 69 This small study showed that both CsA and MTX are clinically effective, relatively safe, and well tolerated. Most systemic agents have a reasonable efficacy and safety profile based on limited studies in other populations (refer to Table 3 for the most common AEs).
Cyclosporine A
CsA is an oral immunosuppressant acting to reduce T cell proliferation as well as IL-2 and calcineurin production. 1 Data from retrospective reviews 70-73 and a single RCT 69 demonstrate a reasonable safety and efficacy profile in pediatric AD. CsA is fast acting and efficacious in treating pediatric AD but has high relapse rates and a concerning safety profile, especially with respect to long-term use beyond 1 year. 21 Methotrexate MTX is a folic acid synthesis inhibitor with broad immunosuppressive properties. 1 Data for its use in pediatric AD include 1 RCT 69,74 and a number of retrospective reviews [75] [76] [77] that demonstrate a reasonable efficacy and safety profile. MTX is used widely in North America, most commonly as first-or second-line systemic therapy, 68 in part due to its low cost.
Azathioprine
AZA is a purine analog that inhibits DNA synthesis and, as such, reduces the proliferation of inflammatory cells. 1 It has a gradual onset of action with a reasonable efficacy and safety profile. [78] [79] [80] [81] [82] Low thiopurine methyltransferase (TPMT) activity is associated with increased myelotoxicity, and TPMT activity screening tests should be measured in pediatric patients at baseline. 1 Long-term adverse effects in pediatric AD have not been studied; however, AZA has been shown to increase the risk of non-melanoma skin cancer and lymphoma in inflammatory bowel disease patients. 66 
Mycophenolate
Mycophenolate products, including MMF and mycophenolate sodium, act as purine synthesis inhibitors that selectively affect B and T cells. 1 Although not used widely, MMF remains a systemic therapy option for pediatric AD when other options are not efficacious or tolerated.
Prednisone
Prednisone is a systemic corticosteroid with approval for the treatment of AD in a number of countries; however, its routine use is generally discouraged. Due to a high relapse rate and concerning safety profile, systemic corticosteroids should only be used for special circumstances and as rescue treatment according to a consensus statement by the International Eczema Council. 83 Long-term use is associated with adverse effects such as Cushing syndrome, cataracts, glaucoma, and growth impairment, among others. 83 It should be reserved for the shortest course possible, such as transitioning to a systemic therapy with slower onset of action. 7
Dupilumab
Dupilumab is the only systemic biologic indicated for the treatment of pediatric AD in children aged 12 and older. It has a targeted mechanism of action blocking the shared receptor subunit for IL-4 and IL-13 with the most rigorous clinical trial data in pediatric AD to date. 84 It has a favourable efficacy and safety profile in both adults and children with moderate-to-severe AD who have failed topical therapy. [84] [85] [86] [87] Dupilumab is administered subcutaneously. It has a rapid onset of action with long-term efficacy and safety data in adults. Conjunctivitis has been noted in a small proportion of patients taking dupilumab, particularly those with severe AD or prior history. HCPs should proactively or reactively manage their patients as needed. 88, 89 Emerging Therapies Novel targeted therapies are being studied in children and adolescents with moderate-to-severe AD, including both topical and systemic Janus kinase (JAK) inhibitors as well as other systemic biologics. See Table 4 for a summary of emerging topical and systemic therapies. Abrocitinib and upadacitinib, both JAK inhibitors, are in phase 3 clinical trials for adolescent AD (age 12-17 years). Further studies in younger age groups are underway for dupilumab, the IL-4/ IL-13 inhibitor, including in patients aged ≥6 months-6 years and 6-11 years. Tralokinumab, an IL-13 inhibitor, has a phase 
